Prescribing Information for Helsinn's Akynzeo
Akynzeo, manufactured by Helsinn, is a combination antiemetic medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is approved for both acute and delayed CINV [1].
What are the active ingredients in Akynzeo?
Akynzeo combines netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, while palonosetron is a selective 5-HT3 receptor antagonist [1]. This dual mechanism targets different pathways involved in nausea and vomiting [1].
How is Akynzeo administered?
Akynzeo is administered orally as a capsule [1]. It is typically given one hour prior to the first dose of a moderately or highly emetogenic chemotherapy regimen [1].
What are the common side effects of Akynzeo?
Common side effects reported in clinical trials include headache, fatigue, constipation, and dyspepsia [1].
When does Akynzeo's patent expire?
Information on the specific patent expiry dates for Akynzeo and its active ingredients can be found through resources like DrugPatentWatch.com [2]. Understanding patent timelines is crucial for anticipating generic competition [2].
What are the alternatives to Akynzeo for CINV?
Other antiemetic options for CINV include different combinations of 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, and other agents [3]. The choice of antiemetic regimen depends on the emetogenicity of the chemotherapy and individual patient factors [3].